Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Executive summary

Conclusions

1 evidence topic · 18 sources

Summary

COMPASS Pathways completed its NDA for COMP360 in TRD on November 9, 2026, and its Commissioner's National Priority Voucher “could shorten review times to 1-2 months”. Psilocybin is in Schedule I; launch is anticipated in the first half of 2027, subject to FDA approval and DEA rescheduling. TRD affected 2.8 million (30.9%) of 8.9 million US adults with medication-treated MDD and accounted for $43.8 billion in annual burden.

In COMP005 (258 participants), one 25 mg dose reduced MADRS score more than placebo at Week 6 (difference -3.6; p<0.001). In COMP006 (581 participants), two 25 mg doses reduced it more than two 1 mg doses (-3.8; p<0.001). Observed or open-label durability data show an average 13-point reduction at Week 52 in the COMP005 25 mg arm after another dose, and benefit maintained through at least Week 26 by the 39% of the COMP006 25 mg arm with a clinically meaningful Week 6 reduction. Phase 3 results come from company filings, presentations, and congress abstracts. In the peer-reviewed phase 2b COMP001 trial (233 participants), the Week 3 difference for 25 mg versus 1 mg was -6.6 (P<0.001); response and remission at Week 3 were supportive of the primary result, and sustained response at 12 weeks was not.

Headache, nausea, and visual hallucination were common, primarily on dosing days. Serious TEAEs through Week 26 of COMP005 occurred in 4.7% (COMP360) and 2.3% (placebo), and the data safety monitoring board found no clinically meaningful suicidality imbalance in either trial.

Sessions last six to eight hours at a certified treatment center, with two monitoring healthcare providers in the trials and an expected REMS templated on the Spravato REMS.

No price is published. ICER's final evidence report is scheduled for 06/21/2027; published psilocybin analyses report $117,517 per QALY gained or cost savings.

Limitations are functional unblinding, no active comparator, preliminary phase 3 data with no COMP006 registry results, and discrepancies between company sources (40 or 32 COMP005 sites; 581 dosed or 572 enrolled in COMP006).